Splenectomy may be a safe therapeutic options for children with nonmalignant hematologic diseases who have proper vaccinations and follow-up care.
Neither transcriptional nor proteomic profiling revealed significant differences between F- and A-cells at baseline or after HbF-inducing treatment.
When compared with placebo, luspatercept increased the percentage of patients with transfusion-dependent beta-thalassemia who had a reduction in transfusion burden.
As the life expectancy for patients with beta thalassemia continues to increase, more and more patients are experiencing age-related complications.
Both event-free and overall survival at 3 years were 96% for patients with transfusion-dependent thalassemia who underwent transplant.
Hypothyroidism, hyperglycemia, and low adrenocorticotrophic hormone levels are associated with lower bone mass in patients with thalassemia major.
Mice with thalassemia with ERFE loss exhibited increased osteoblast and osteoclast activity and decreased bone formation.
A new oral iron chelator, deferasirox, may confer long-term benefits to patients with beta thalassemia major.
Researchers analyzed 1110 patients who had received transplanted grafts from HLA-matched and mismatched relatives and unrelated donors.
Allogeneic hematopoietic cell transplantation was tolerated well by pediatric patients with sickle cell disease and transfusion-dependent thalassemia.
